In this episode of the Wild Health Podcast, Dr.'s Carl Seger and Mike Stone dive into the exciting and controversial topic of GLP-1, particularly drugs like Ozempic and semaglutide. The conversation kicks off with the latest news about GLP-1 agonists, originally developed for diabetes but now being explored for a host of other potential benefits, including weight loss, cardiovascular health, and even the prevention of cognitive decline and Alzheimer’s disease.

The discussion also highlights the recent buzz around a study presented at the Alzheimer's Association International Conference, which suggests that GLP-1 agonists might help reduce the risk of Alzheimer's by reducing inflammation in the brain. Carl and Mike delve into the mechanisms of how these drugs might work beyond glucose control, exploring their potential anti-inflammatory effects and their implications for treating chronic diseases. They also discuss the ongoing phase 3 clinical trials that could provide more definitive answers.

The episode wraps up with a focus on the importance of a holistic approach to health, emphasizing that while drugs like GLP-1 agonists could play a significant role, they are not a one-size-fits-all solution. They stress the need for maintaining a balanced diet, exercise, and body recomposition rather than merely focusing on weight loss.

What Do Doctors ACTUALLY Know About GLP-1's? 36:06 Share

Wild Health Podcast

Shownotes Transcript

What Do Doctors ACTUALLY Know About GLP-1's?